TOP TEN perturbations for 1553634_a_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1553634_a_at
Selected probe(set): 1553634_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1553634_a_at (1553634_a_at) across 6673 perturbations tested by GENEVESTIGATOR:
atopic dermatitis study 12 (non-lesional; adults) / atopic dermatitis study 12 (non-lesional; children)
Relative Expression (log2-ratio):-1.8646984Number of Samples:20 / 19
Experimental | atopic dermatitis study 12 (non-lesional; adults) |
Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
Control | atopic dermatitis study 12 (non-lesional; children) |
Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. |
BEZ235 study 1 (3.606 uM) / vehicle (DMSO) treated A2058 cell samples
Relative Expression (log2-ratio):1.8260956Number of Samples:4 / 4
Experimental | BEZ235 study 1 (3.606 uM) |
A2058 cells treated with 3.606 uM NVP-BEZ235 for 24hours. The concentration corresponding to the IC90 of BKM120. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine. BEZ235 is a mTOR/PI3K inhibitor; alternative names: [NVP-BEZ235] ATC code:--- | |
Control | vehicle (DMSO) treated A2058 cell samples |
A2058 cells treated with vehicle (0.1% DMSO) for 24hours. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine. |
juvenile psoriatic arthritis study 1 / normal PBMC sample
Relative Expression (log2-ratio):-1.7796631Number of Samples:2 / 29
Experimental | juvenile psoriatic arthritis study 1 |
Peripheral blood mononuclear cell (PBMC) samples from children with juvenile psoriatic arthritis. All patients were free of disease modifying antirheumatic drugs. | |
Control | normal PBMC sample |
Peripheral blood mononuclear cell (PBMC) samples from healthy children; age (mean ± SD): 10.8 ± 5.3 years. |
psoriasis study 11 (lesional; brodalumab; 15d; 700mg) / psoriasis study 11 (lesional; baseline)
Relative Expression (log2-ratio):1.686985Number of Samples:8 / 25
Experimental | psoriasis study 11 (lesional; brodalumab; 15d; 700mg) |
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code: | |
Control | psoriasis study 11 (lesional; baseline) |
Lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment. |
atopic dermatitis study 12 (lesional; adults) / atopic dermatitis study 12 (lesional; children)
Relative Expression (log2-ratio):-1.6836033Number of Samples:20 / 18
Experimental | atopic dermatitis study 12 (lesional; adults) |
Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
Control | atopic dermatitis study 12 (lesional; children) |
Lesional popliteal skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All biopsy specimens were from chronic lesions present for more than 72 hours. All patients had moderate-to-severe disease with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. |
atopic dermatitis study 12 (lesional; adults) / normal skin tissue (adults)
Relative Expression (log2-ratio):-1.6712351Number of Samples:20 / 11
Experimental | atopic dermatitis study 12 (lesional; adults) |
Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
Control | normal skin tissue (adults) |
Skin biopsy samples from healthy adults (age range 38–57 years). |
psoriasis study 11 (lesional; brodalumab; 15d; 700mg) / psoriasis study 11 (lesional; placebo; 15d)
Relative Expression (log2-ratio):1.5739107Number of Samples:8 / 5
Experimental | psoriasis study 11 (lesional; brodalumab; 15d; 700mg) |
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code: | |
Control | psoriasis study 11 (lesional; placebo; 15d) |
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with placebo. |
peptidoglycan study 1 / mock treated neonatal neutrophils
Relative Expression (log2-ratio):1.5306454Number of Samples:3 / 3
Experimental | peptidoglycan study 1 |
Healthy neonatal neutrophils with ≥ 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery treated with peptidoglycan isolated from S. aureus (10 ug/ml) for 4 hours. | |
Control | mock treated neonatal neutrophils |
Healthy neonatal neutrophils with ≥ 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery mock treated for 4 hours. |
BEZ235 study 1 (IC90) / vehicle (DMSO) treated A2058 cell samples
Relative Expression (log2-ratio):1.5236158Number of Samples:4 / 4
Experimental | BEZ235 study 1 (IC90) |
A2058 cells treated with NVP-BEZ235 for 24hours at an IC90 concentration. Concentration of IC90 was judged by reduction of pAkt levels (S473P-Akt inhibition) and the value is not clear from the article. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine. BEZ235 is a mTOR/PI3K inhibitor; alternative names: [NVP-BEZ235] ATC code:--- | |
Control | vehicle (DMSO) treated A2058 cell samples |
A2058 cells treated with vehicle (0.1% DMSO) for 24hours. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine. |
glioma study 16 (astrocytoma) / normal brain tissue
Relative Expression (log2-ratio):1.5113859Number of Samples:8 / 2
Experimental | glioma study 16 (astrocytoma) |
Primary astrocytoma tissues obtained from the operating room. Tumors were diagnosed and graded according to the current WHO classification (grade III-IV). | |
Control | normal brain tissue |
Normal brain tissue sample from healthy donors. |